

1 Washington Vaccine Association 2 **Board of Directors Meeting** 3 April 18, 2024; 2:00-4:00 p.m. (PT) 4 5 I. Attendance. This meeting was conducted virtually. Participating in all or part of the meeting were the following individuals: 6 7 8 Cheri Cagle, Stakeholder Liaison Directors 9 John Dunn, MPH, MD, Kaiser Permanente, Chair 22 10 Beth Harvey, MD, South Sound Pediatrics, Vice Chair 23 Helms & Company, Inc. 11 Ed Marcuse, MD, MPH, FPIDS, University of 24 Patrick Miller, MPH, WVA, Administrative Director Washington, Secretary 25 Ashley Ithal, MPH, WVA, Program Support 12 Steven Caplow, Esq., DWT LLP 26 Leslie Walker, CPA, Mason+Rich, PA 13 Kara Manley, United Healthcare 27 15 Nicole Saint Clair, MD, Regence 28 Others 16 Pam Sheffield, MD, Aetna 29 Supriya Ramanathan, MD, Aetna Jamilia Sherls-Jones, Washington Department of Health30 Anne Redman, Esq., Perkins Coie 17 31 Janel Jorgenson, Washington Department of Health 18 19 WVA 32 Breelyn Young, GSK Julia Walter Zell, MA., Esq., Executive Director 33 Rick Hourigan, MD, Cigna 20 34 35 II. Summary of Actions Taken and/or Recommended 36 37 Actions Taken (votes adopted) To approve the minutes of the February 22, 2024, Board Meeting. 38 i. 39 ii. Vote to confirm Nicole Saint Clair as a Board Member. iii. Vote to approve 2024-25 Administrative Budget. 40 41 iv. Vote to approve 2024-25 Assessment Grid. 42 III. Minutes 43 44 45 Welcome and Introductions 46 Dr. Dunn called the meeting to order at 2:00 p.m. Ms. Zell provided a notice of recording for the purposes of the 47 meeting minutes. The recording will be deleted once the meeting minutes are approved. Mr. Miller conducted a roll call at Ms. Zell's request. 48 49 50 Consent Calendar Dr. Dunn asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously 51 52 53 **VOTED:** To approve the minutes of the February 22, 2024, Board Meeting. 54 55 Ms. Zell welcomed Dr. Nicole Saint Clair from Regence and invited her to introduce herself. Dr. Dunn asked for a motion to confirm Dr. Saint Clair as a Board Member. Upon motion duly made and seconded, it was unanimously 56 57 **VOTED:** Vote to confirm Nicole Saint Clair as a Board Member as a WVA Board Member 58 59 from Regence, whose term expires in 2027 pursuant to RCW 70.290.030 (3)(a). 60 IV. Financial Updates 61 62 63 **Unaudited Financials** 64 Mr. Miller reviewed the financial statements through March 2024. Mr. Miller reported that the WVA has been reducing cash, as planned, and that administrative expenses were slightly ahead of budget, which is consistent with 65 the financial statements of the last seven months. 66

FY25 Administrative Budget and FY25 Assessment Grid

67

68



Ms. Zell provided an overview of the WVA Vaccine Assessment Grid (Grid) modeling process and history. Mr. Miller summarized the FY25 Grid model process, the FY25 administrative budget, and the FY25 Grid model assumptions and projections. Mr. Miller stated that the next step in the process after this meeting is presenting the Grid at next week's Operations Committee for adoption. Mr. Miller highlighted the current efforts to onboard providers not currently submitting dosage-based assessments (DBA), and the FY25 vaccine additions, changes, and retired vaccines / biologics. Mr. Miller reviewed the cash model options for the next three years with the recommendation to increase the Grid in FY25 and hold it steady for the following two years. Ms. Zell added information about reserve projections being based on current efforts. Discussion ensued and concluded with consensus of the presented FY25 administrative budget and Grid model assumptions.

Dr. Dunn asked for a motion to approve the 2024-25 Administrative Budget. Upon motion duly made and seconded, it was unanimously

## **VOTED:** To approve the 2024-25 Administrative Budget.

Dr. Dunn asked for a motion to approve the changes to the 2024-25 Assessment Grid. Upon motion duly made and seconded, it was unanimously

#### **VOTED:** To approve the 2024-25 Assessment Grid.

#### FY2024 Audit Preparation

Ms. Zell provided an overview of the next steps for the FY2024 audit with Clifton Larsen Allen (CLA). The audit will take place in August, the draft will be shared with the Finance Committee in September, and the final version will be adopted by the Board in November.

## V. WA DOH Updates

Ms. Sherls-Jones provided an update on currently commercially available immunizations from the Department of Health's (DOH's) Childhood Vaccine Program (CVP) for provider ordering, including the JYNNEOS®, Penbraya<sup>TM</sup>, and Beyfortus<sup>TM</sup> immunizations. She updated the group on efforts to update the DOH's immunization dashboard and that once the dashboard updates go live that the DOH will distribute a communication.

#### VI. ED/AD Updates

### Operational Review – 2020-2024

 Ms. Zell and Mr. Miller provided an overview presentation of changes and improvements made to WVA operations and data management between 2020 and present and highlighted accomplishments to date.

## Non-Traditional Provider Outreach and Engagement

 Ms. Ithal provided an update on non-traditional provider outreach efforts inclusive of Direct Care Practices (DCPs), School Based Health Clinics (SBHCs), and Pharmacies to understand current adoption rates of the WVA DBA process. She noted that both providers and payers will be required to update their systems to support DBA submission and payment.

113 Ms. Sherls-Jones updated the group on planned efforts within the DOH regarding LHJ engagement.

# VII. Public Comments - None.

### VIII. Executive Session - Confidential.

#### IX. Closing

With no further business before the Board, Dr. Dunn closed the meeting at 4:18 p.m.